Filing Details
- Accession Number:
- 0001209191-23-002433
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-01-06 17:39:56
- Reporting Period:
- 2023-01-04
- Accepted Time:
- 2023-01-06 17:39:56
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1652130 | Intellia Therapeutics Inc. | NTLA | In Vitro & In Vivo Diagnostic Substances (2835) | 364785571 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1777421 | Laura Sepp-Lorenzino | C/O Intellia Therapeutics, Inc. 40 Erie Street; Suite 130 Cambridge MA 02139 | Evp, Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2023-01-04 | 2,508 | $37.21 | 19,959 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-01-05 | 1,641 | $38.22 | 18,318 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-01-05 | 689 | $39.10 | 17,629 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023.
- The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.80 to $38.78, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 5, 2023 at each separate price.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.98 to $39.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 5, 2023 at each separate price.